Clinical Trial Comparator Supply in Canada: The Process From Protocol to Depot
How comparator supply actually runs for a Canadian trial: specification, Division 5 basis, sourcing documentation, blinding sites, depot release and realistic timelines.
What the sponsor is buying
In an active-control trial the comparator is a commercial medicine. The sponsor must show an auditor, years later, where every unit came from, how it was stored, and that it was the product the protocol names. The supplier's job is therefore documentation as much as logistics.
Step 1 — Fix the comparator specification
Write down the molecule, strength, dosage form, pack, and acceptable source markets. Health Canada's Drug Product Database gives the Canadian DIN and its status [1]; if the protocol needs a presentation that is not marketed in Canada, the Nexara Health DIN page lists same-molecule registrations in other regulators' registers so the sourcing market can be chosen before the CTA is filed.
Step 2 — Confirm the regulatory basis
Drugs used in a Canadian trial are governed by Division 5 of the Food and Drug Regulations. A comparator that is authorized and marketed in Canada is used under the trial's Clinical Trial Application; a comparator imported from abroad must be identified in the CTA and imported by a party holding the appropriate licence [2]. Sponsors importing drugs for a trial must also meet the labelling and record-keeping requirements in Division 5 [2].
Step 3 — Source and document
For each lot the supplier should provide: manufacturer and marketing authorization holder, batch number, expiry, Certificate of Analysis, and the chain-of-custody record from the source wholesaler to the Canadian depot. For cold-chain products, the temperature log for every leg. Good Distribution Practices are enforced in Canada through the DEL framework and the GUI-0069 guidance on storage and transport [3].
Step 4 — Blinding, packaging, labelling
Over-encapsulation or relabelling for blinding is a fabrication/packaging activity that must be done at a site whose DEL covers it [4]. Ask the supplier which licensed site performs the work and request the site's licence number.
Step 5 — Depot, release, resupply
Quarantine on receipt, QA release against the CoA and temperature record, then site distribution. Build the resupply forecast from the enrolment curve; comparator expiry dating is usually shorter than IMP, so plan at least one mid-trial resupply.
Typical timeline
Canadian-marketed comparator: 1–2 weeks from PO to depot. Imported comparator from a regulated market: 4–8 weeks including export release, import, and QA release. Add 2–4 weeks where blinding work is required.
Sources
[1] Health Canada, Drug Product Database — https://health-products.canada.ca/dpd-bdpp/
[2] Food and Drug Regulations, Part C Division 5 (Drugs for Clinical Trials Involving Human Subjects) — https://laws-lois.justice.gc.ca/eng/regulations/C.R.C.,_c._870/page-125.html
[3] Health Canada, GUI-0069 Guidelines for temperature control of drug products during storage and transportation — https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-manufacturing-practices/guidance-documents/guidelines-temperature-control-drug-products-storage-transportation-0069.html
[4] Health Canada, Drug Establishment Licences — https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/establishment-licences.html